Zhengye Biotechnology Holding (ZYBT) Fundamentals 2026 — Revenue Analysis | SniperIQ

.43 on the NASDAQ. This SniperIQ fundamentals page covers Zhengye Biotechnology Holding's valuation, profitability (net margin -89.0%), revenue (¥116M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Zhengye Biotechnology Holding's market cap?

Zhengye Biotechnology Holding (ZYBT) has a market capitalization of approximately $68M, trading at

.43 on the NASDAQ. Market cap moves with the live share price.

What is Zhengye Biotechnology Holding's P/E ratio?

Zhengye Biotechnology Holding's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Zhengye Biotechnology Holding?

Zhengye Biotechnology Holding runs a net profit margin of -89.0%, a gross margin of 8.3%, and an operating margin of -77.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Zhengye Biotechnology Holding generate?

Zhengye Biotechnology Holding reported revenue of ¥116M for fiscal year 2025, with net income of -¥70M and earnings per share (EPS) of -1.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Zhengye Biotechnology Holding pay a dividend?

Zhengye Biotechnology Holding does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Zhengye Biotechnology Holding financially healthy?

Zhengye Biotechnology Holding carries a debt-to-equity ratio of 0.30x and a current ratio of 1.14x, with a market beta of -2.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Zhengye Biotechnology Holding a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhengye Biotechnology Holding (ZYBT) the key facts are: market cap $68M, revenue ¥116M, 52-week range 0.616-13.08. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.